While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
A St. Jude Children's Research Hospital-led team found BRCA2 mutations are more common among survivors of non-Hodgkin lymphoma than individuals without cancer.
Despite initial promise, NGS-based MRD detection has not been broadly adopted, but improvements in technology and more clinical utility data may change that.
An array-based analysis involving more than two dozen patients led to a miRNA signature associated with overall survival in primary central nervous system lymphoma.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.
